GM1 ganglioside may slow symptom progression in Parkinson's disease patients

被引：0
|
作者：
Freeston, Sarah [1 ]
机构：
[1] Future Med Ltd, Neurodegenerat Dis Management, Unitec House,2 Albert Pl, London N3 1QB, England
来源：
NEURODEGENERATIVE DISEASE MANAGEMENT | 2013年 / 3卷 / 01期
关键词：
D O I：
10.2217/NMT.13.3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [1] GM1 ganglioside in the treatment of Parkinson's disease
    Schneider, JS
    SPHINGOLIPIDS AS SIGNALING MODULATORS IN THE NERVOUS SYSTEM, 1998, 845 : 363 - 373
  • [2] The Key Role of GM1 Ganglioside in Parkinson's Disease
    Chowdhury, Suman
    Ledeen, Robert
    BIOMOLECULES, 2022, 12 (02)
  • [3] A four-year experience with GM1 ganglioside in Parkinson's disease patients
    Schneider, JS
    Ferraro, S
    Mancall, EL
    NEUROLOGY, 2000, 54 (07) : A278 - A279
  • [4] A delayed start trial of GM1 ganglioside in Parkinson's disease
    Schneider, J. S.
    Sendek, S.
    Gollomp, S. M.
    Colcher, A.
    Cambi, F.
    Du, W.
    MOVEMENT DISORDERS, 2011, 26 : S139 - S139
  • [5] GM1 ganglioside and Alzheimer's disease
    Yanagisawa, Katsuhiko
    GLYCOCONJUGATE JOURNAL, 2015, 32 (3-4) : 87 - 91
  • [6] GM1 ganglioside and Alzheimer’s disease
    Katsuhiko Yanagisawa
    Glycoconjugate Journal, 2015, 32 : 87 - 91
  • [7] The relationship between depletion of brain GM1 ganglioside and Parkinson's disease
    Sonnino, Sandro
    FEBS OPEN BIO, 2023, 13 (09): : 1548 - 1557
  • [8] Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans
    Wu, Gusheng
    Lu, Zi-Hua
    Kulkarni, Neil
    Ledeen, Robert W.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2012, 90 (10) : 1997 - 2008
  • [9] A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients
    Schneider, Jay S.
    Gollomp, Stephen M.
    Sendek, Stephanie
    Colcher, Amy
    Cambi, Franca
    Du, Wei
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 324 (1-2) : 140 - 148
  • [10] A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson’s disease
    J. S. Schneider
    Glycoconjugate Journal, 2022, 39 : 13 - 26
12345